What is the projected market valuation for the Gastric Cancer Treatment Market in 2035?

The projected market valuation for the Gastric Cancer Treatment Market in 2035 is expected to reach 10.08 USD Billion. Read More

What was the market valuation for the Gastric Cancer Treatment Market in 2024?

The market valuation for the Gastric Cancer Treatment Market in 2024 was 3.423 USD Billion. Read More

What is the expected CAGR for the Gastric Cancer Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Gastric Cancer Treatment Market during the forecast period 2025 - 2035 is 10.31%. Read More

Which companies are considered key players in the Gastric Cancer Treatment Market?

Key players in the Gastric Cancer Treatment Market include Roche, Bristol-Myers Squibb, Merck & Co., AstraZeneca, Eli Lilly and Company, Novartis, Amgen, Pfizer, and Bayer. Read More

What are the main treatment types contributing to the Gastric Cancer Treatment Market?

Main treatment types contributing to the market include Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy. Read More

How much revenue is generated from Chemotherapy in the Gastric Cancer Treatment Market?

Revenue generated from Chemotherapy in the Gastric Cancer Treatment Market is projected to grow from 1.2 USD Billion to 3.5 USD Billion. Read More

What is the revenue outlook for Early-Stage Gastric Cancer treatment by 2035?

The revenue outlook for Early-Stage Gastric Cancer treatment is expected to increase from 1.5 USD Billion to 4.5 USD Billion by 2035. Read More

What segment of the Gastric Cancer Treatment Market focuses on side effects management?

The segment focusing on side effects management includes Anti-Nausea Medications, Pain Management Medications, and Supportive Care Measures. Read More

What is the projected revenue for Immunotherapy in the Gastric Cancer Treatment Market?

The projected revenue for Immunotherapy in the Gastric Cancer Treatment Market is expected to rise from 0.273 USD Billion to 0.8 USD Billion. Read More

How does the market for Advanced-Stage Gastric Cancer compare to Early-Stage Gastric Cancer in terms of revenue?

The market for Advanced-Stage Gastric Cancer is projected to generate more revenue, increasing from 1.923 USD Billion to 5.58 USD Billion, compared to Early-Stage Gastric Cancer. Read More

Gastric Cancer Treatment Market

Gastric Cancer Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By Route of Administration (Intravenous, Oral, Subcutaneous), By Side Effects Management (Anti-Nausea Medications, Pain Management Medications, Supportive Care Measures), By Disease Stage (Early-Stage Gastric Cancer, Advanced-Stage Gastric Cancer), By Molecular Biomarkers (HER2-Positive Gastric Cancer, MSI-High Gastric Cancer, EGFR-Positive Gastric Cancer) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

10.31%

2024 Market Size

$ 3.42 Billion

2035 Market Size

$ 10.08 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/25461-HCR | Pages: 128 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Surgery
  2. 4.1.2 Chemotherapy
  3. 4.1.3 Radiation Therapy
  4. 4.1.4 Targeted Therapy
  5. 4.1.5 Immunotherapy
2. 4.2 Healthcare, BY Route of Administration (USD Billion)
  1. 4.2.1 Intravenous
  2. 4.2.2 Oral
  3. 4.2.3 Subcutaneous
3. 4.3 Healthcare, BY Side Effects Management (USD Billion)
  1. 4.3.1 Anti-Nausea Medications
  2. 4.3.2 Pain Management Medications
  3. 4.3.3 Supportive Care Measures
4. 4.4 Healthcare, BY Disease Stage (USD Billion)
  1. 4.4.1 Early-Stage Gastric Cancer
  2. 4.4.2 Advanced-Stage Gastric Cancer
5. 4.5 Healthcare, BY Molecular Biomarkers (USD Billion)
  1. 4.5.1 HER2-Positive Gastric Cancer
  2. 4.5.2 MSI-High Gastric Cancer
  3. 4.5.3 EGFR-Positive Gastric Cancer
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
6. 6.6 US MARKET ANALYSIS BY DISEASE STAGE
7. 6.7 US MARKET ANALYSIS BY MOLECULAR BIOMARKERS
8. 6.8 CANADA MARKET ANALYSIS BY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
11. 6.11 CANADA MARKET ANALYSIS BY DISEASE STAGE
12. 6.12 CANADA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 GERMANY MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
17. 6.17 GERMANY MARKET ANALYSIS BY DISEASE STAGE
18. 6.18 GERMANY MARKET ANALYSIS BY MOLECULAR BIOMARKERS
19. 6.19 UK MARKET ANALYSIS BY TYPE
20. 6.20 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
21. 6.21 UK MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
22. 6.22 UK MARKET ANALYSIS BY DISEASE STAGE
23. 6.23 UK MARKET ANALYSIS BY MOLECULAR BIOMARKERS
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
26. 6.26 FRANCE MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
27. 6.27 FRANCE MARKET ANALYSIS BY DISEASE STAGE
28. 6.28 FRANCE MARKET ANALYSIS BY MOLECULAR BIOMARKERS
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 RUSSIA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
32. 6.32 RUSSIA MARKET ANALYSIS BY DISEASE STAGE
33. 6.33 RUSSIA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
34. 6.34 ITALY MARKET ANALYSIS BY TYPE
35. 6.35 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
36. 6.36 ITALY MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
37. 6.37 ITALY MARKET ANALYSIS BY DISEASE STAGE
38. 6.38 ITALY MARKET ANALYSIS BY MOLECULAR BIOMARKERS
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
41. 6.41 SPAIN MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
42. 6.42 SPAIN MARKET ANALYSIS BY DISEASE STAGE
43. 6.43 SPAIN MARKET ANALYSIS BY MOLECULAR BIOMARKERS
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DISEASE STAGE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY MOLECULAR BIOMARKERS
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE
51. 6.51 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
52. 6.52 CHINA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
53. 6.53 CHINA MARKET ANALYSIS BY DISEASE STAGE
54. 6.54 CHINA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
55. 6.55 INDIA MARKET ANALYSIS BY TYPE
56. 6.56 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
57. 6.57 INDIA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
58. 6.58 INDIA MARKET ANALYSIS BY DISEASE STAGE
59. 6.59 INDIA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
62. 6.62 JAPAN MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
63. 6.63 JAPAN MARKET ANALYSIS BY DISEASE STAGE
64. 6.64 JAPAN MARKET ANALYSIS BY MOLECULAR BIOMARKERS
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DISEASE STAGE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
73. 6.73 MALAYSIA MARKET ANALYSIS BY DISEASE STAGE
74. 6.74 MALAYSIA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
77. 6.77 THAILAND MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
78. 6.78 THAILAND MARKET ANALYSIS BY DISEASE STAGE
79. 6.79 THAILAND MARKET ANALYSIS BY MOLECULAR BIOMARKERS
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
82. 6.82 INDONESIA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
83. 6.83 INDONESIA MARKET ANALYSIS BY DISEASE STAGE
84. 6.84 INDONESIA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
88. 6.88 REST OF APAC MARKET ANALYSIS BY DISEASE STAGE
89. 6.89 REST OF APAC MARKET ANALYSIS BY MOLECULAR BIOMARKERS
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
93. 6.93 BRAZIL MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
94. 6.94 BRAZIL MARKET ANALYSIS BY DISEASE STAGE
95. 6.95 BRAZIL MARKET ANALYSIS BY MOLECULAR BIOMARKERS
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
98. 6.98 MEXICO MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
99. 6.99 MEXICO MARKET ANALYSIS BY DISEASE STAGE
100. 6.100 MEXICO MARKET ANALYSIS BY MOLECULAR BIOMARKERS
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
104. 6.104 ARGENTINA MARKET ANALYSIS BY DISEASE STAGE
105. 6.105 ARGENTINA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE STAGE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DISEASE STAGE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY MOLECULAR BIOMARKERS
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DISEASE STAGE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY SIDE EFFECTS MANAGEMENT
125. 6.125 REST OF MEA MARKET ANALYSIS BY DISEASE STAGE
126. 6.126 REST OF MEA MARKET ANALYSIS BY MOLECULAR BIOMARKERS
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY SIDE EFFECTS MANAGEMENT, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY SIDE EFFECTS MANAGEMENT, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY MOLECULAR BIOMARKERS, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY MOLECULAR BIOMARKERS, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.2.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.2.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.3.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.3.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.4.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.4.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.5.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.5.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.6.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.6.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.7.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.7.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.8.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.8.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.9.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.9.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.10.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.10.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.11.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.11.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.12.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.12.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.13.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.13.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.14.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.14.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.15.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.15.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.16.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.16.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.17.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.17.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.18.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.18.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.19.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.19.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.20.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.20.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.21.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.21.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.22.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.22.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.23.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.23.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.24.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.24.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.25.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.25.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.26.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.26.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.27.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.27.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.28.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.28.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.29.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.29.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY SIDE EFFECTS MANAGEMENT, 2025-2035 (USD Billion)
  4. 7.30.4 BY DISEASE STAGE, 2025-2035 (USD Billion)
  5. 7.30.5 BY MOLECULAR BIOMARKERS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Gastric Cancer Treatment Market Segmentation

Gastric Cancer Treatment Market By Type (USD Billion, 2025-2035)

Surgery
Chemotherapy
Radiation Therapy
Targeted Therapy
Immunotherapy

Gastric Cancer Treatment Market By Route of Administration (USD Billion, 2025-2035)

Intravenous
Oral
Subcutaneous

Gastric Cancer Treatment Market By Side Effects Management (USD Billion, 2025-2035)

Anti-Nausea Medications
Pain Management Medications
Supportive Care Measures

Gastric Cancer Treatment Market By Disease Stage (USD Billion, 2025-2035)

Early-Stage Gastric Cancer
Advanced-Stage Gastric Cancer

Gastric Cancer Treatment Market By Molecular Biomarkers (USD Billion, 2025-2035)

HER2-Positive Gastric Cancer
MSI-High Gastric Cancer
EGFR-Positive Gastric Cancer

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”